AR048361A1 - Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos - Google Patents

Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos

Info

Publication number
AR048361A1
AR048361A1 ARP050101294A ARP050101294A AR048361A1 AR 048361 A1 AR048361 A1 AR 048361A1 AR P050101294 A ARP050101294 A AR P050101294A AR P050101294 A ARP050101294 A AR P050101294A AR 048361 A1 AR048361 A1 AR 048361A1
Authority
AR
Argentina
Prior art keywords
group
optionally substituted
heterocyclic
atoms
independently selected
Prior art date
Application number
ARP050101294A
Other languages
English (en)
Inventor
Hitoshi Kubota
Masakatsu Sugahara
Mariko Furukawa
Mayumi Takano
Daisuke Motomura
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of AR048361A1 publication Critical patent/AR048361A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

La presente trata de derivados de tetrahidroquinolina o una sal farmacéuticamente aceptable del mismo que posee una actividad inhibitoria contra proteína de transferencia de colesteril éster (CETP). Reivindicacion 1: Un compuesto caracterizado por que posee a formula (1): en donde R1 es un átomo de H, un grupo alcoxicarbonilo opcionalmente sustituido, un grupo carbamoilo opcionalmente sustituido, un grupo alquilo opcionalmente sustituido, un grupo alcanoilo opcionalmente sustituido, un grupo monocíclico o heterocíclico bicíclico saturado o no saturado que contiene 1 a 4 heteroátomos independientemente seleccionados de O, S y átomos de N (el grupo heterocíclico es opcionalmente sustituido), o un grupo carbonilo monocíclico o heterocíclico bicíclico saturado o no saturado que contiene 1 a 4 heteroátomos independientemente seleccionados de átomos de O, S y N (el grupo heterocíclico opcionalmente sustituido); R2 es un átomo de H o un grupo alquilo opcionalmente sustituido; R3 es un átomo de H o un grupo alquilo opcionalmente sustituido; R4 es un grupo alquileno opcionalmente sustituido, R5 es un grupo monocíclico o heterocíclico bicíclico saturado o no saturado que contiene 1 a 4 heteroátomos independientemente seleccionados de átomos de O, S y N, en donde el grupo heterocíclico es sustituido por 1 a 5 sustituyentes seleccionados de los grupos siguientes, o dicho grupo heterocíclico es sustituido por 1 a 5 sustituyentes seleccionados de grupos siguientes y además por un átomo halogeno, un grupo oxo y/o hidroxilo: grupo ciano, grupo nitro, grupo carboxilo, grupo sulfo, grupo alquilo C3-10, grupo alquilo sustituido, grupo cicloalquilo opcionalmente sustituido, grupo alquenilo opcionalmente sustituido, grupo alcoxilo C3-10, grupo alcoxilo sustituido, grupo cicloalcoxilo opcionalmente sustituido, grupo alcoxicarbonilo opcionalmente sustituido, grupo carbamoilo opcionalmente sustituido, grupo carbamimidoilo opcionalmente sustituid, grupo alquiltio opcionalmente sustituido, grupo alquilsulfinilo opcionalmente sustituido, grupo alquilsulfonilo opcionalmente sustituido, grupo amino opcionalmente sustituido,, grupo sulfamoilo opcionalmente sustituido,, grupo alcanoilo opcionalmente sustituido,, grupo monocíclico o heterocíclico bicíclico saturado o no saturado que contiene 1 a 4 heteroátomos independientemente seleccionados de átomos de O, S y N (el grupo heterocíclico es opcionalmente sustituido), un grupo oxilo monocíclico o heterocíclico bicíclico saturados o no saturado que contiene 1 a 4 heteroátomos seleccionados independientemente de átomos de O, S y N (el grupo oxilo heterocíclico es opcionalmente sustituido), y un grupo carbonilo monocíclico o heterocíclico bicíclico saturado o no saturado que contiene 1 a 4 heteroátomos independientemente seleccionados de átomos de O, S y N (el grupo carbonilo heterocíclico es opcionalmente sustituido); R6, R7, R8 y R9 son independientemente un átomo de H, un átomo halogeno, un grupo hidroxilo, un grupo nitro, un grupo ciano, un grupo alquilo opcionalmente sustituido,, un grupo alcoxilo opcionalmente sustituido,, un grupo alquilsulfonilo opcionalmente sustituido o un grupo amino opcionalmente sustituido; o R6 y R7, o R7 y R8, o R8 y R9 pueden combinarse en los extremos para formar un grupo alquileno cuyo grupo alquileno puede contener 1 a 3 heteroátomos independientemente seleccionados de los átomos de N, S y O, y puede tener un sustituyente(s); y R10 es un anillo aromático que contiene opcionalmente 1 a 3 heteroátomos independientemente seleccionados de átomos de O, S y N (el anillo aromático es opcionalmente sustituido), o una sal farmacéuticamente aceptable del mismo.
ARP050101294A 2004-04-02 2005-04-01 Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos AR048361A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004109550 2004-04-02

Publications (1)

Publication Number Publication Date
AR048361A1 true AR048361A1 (es) 2006-04-19

Family

ID=34963484

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050101294A AR048361A1 (es) 2004-04-02 2005-04-01 Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos
ARP170100115A AR107377A2 (es) 2004-04-02 2017-01-17 Compuestos derivados de tetrahidroquinolina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170100115A AR107377A2 (es) 2004-04-02 2017-01-17 Compuestos derivados de tetrahidroquinolina

Country Status (25)

Country Link
US (2) US7872126B2 (es)
EP (1) EP1730152B1 (es)
JP (1) JP4565077B2 (es)
KR (1) KR100905684B1 (es)
CN (2) CN101381345A (es)
AR (2) AR048361A1 (es)
AT (1) ATE556077T1 (es)
AU (1) AU2005228290B2 (es)
BR (1) BRPI0509364B8 (es)
CA (1) CA2560402C (es)
DK (1) DK1730152T3 (es)
EA (1) EA011670B1 (es)
EC (1) ECSP066967A (es)
ES (1) ES2383900T3 (es)
IL (1) IL178195A (es)
MX (1) MXPA06011415A (es)
MY (1) MY158055A (es)
NO (1) NO20065011L (es)
NZ (1) NZ550268A (es)
PL (1) PL1730152T3 (es)
PT (1) PT1730152E (es)
TW (1) TWI338684B (es)
UA (1) UA90269C2 (es)
WO (1) WO2005095409A2 (es)
ZA (1) ZA200608117B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
WO2006012093A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
EP1848430B1 (en) 2004-12-31 2017-08-02 Dr. Reddy's Laboratories Ltd. Novel benzylamine derivatives as cetp inhibitors
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
JP4531027B2 (ja) * 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
CA2625416A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7652023B2 (en) 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007107843A1 (en) * 2006-03-22 2007-09-27 Pfizer Products Inc. Methods of treatment with cetp inhibitors
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
CN102731451B (zh) * 2006-06-27 2015-07-29 武田药品工业株式会社 稠环化合物
US7582691B2 (en) * 2007-01-17 2009-09-01 Sabic Innovative Plastics Ip B.V. Poly(arylene ether) compositions and articles
JP4834699B2 (ja) * 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
PE20090982A1 (es) 2007-11-05 2009-08-13 Novartis Ag Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
AU2012202172B2 (en) * 2007-11-05 2013-08-29 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
EP2229356B1 (en) 2007-12-03 2011-10-12 Novartis AG 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
KR20120036850A (ko) 2009-05-15 2012-04-18 노파르티스 아게 알도스테론 신타제 억제제로서의 벤족사졸론 유도체
MA33358B1 (fr) 2009-05-15 2012-06-01 Novartis Ag Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase
KR101442897B1 (ko) 2009-05-28 2014-09-23 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체
AR076706A1 (es) 2009-05-28 2011-06-29 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de neprilisina
JP5654608B2 (ja) 2009-11-17 2015-01-14 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのアリール−ピリジン誘導体
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
WO2011064376A1 (en) 2009-11-30 2011-06-03 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
TWI506025B (zh) * 2010-07-09 2015-11-01 Daiichi Sankyo Co Ltd 取代吡啶化合物
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
MX2014001849A (es) 2011-08-18 2014-10-24 Reddys Lab Ltd Dr Compuestos de amina heterociclicos sustituidos como inhibidores de proteina de transferencia de ester colesterilo (cetp).
CN103958511A (zh) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
JP6097225B2 (ja) * 2012-01-06 2017-03-15 第一三共株式会社 置換ピリジン化合物の酸付加塩
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
MX367525B (es) 2013-02-14 2019-08-26 Novartis Ag Derivados de ácido bisfenil-butanoico fosfónico sustituido como inhibidores de la endopeptidasa neutra (nep).
UY35670A (es) 2013-07-25 2015-02-27 Novartis Ag Polipéptidos cíclicos para el tratamiento de insuficiencia cardíaca
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
JP6263271B2 (ja) * 2014-02-05 2018-01-17 田辺三菱製薬株式会社 心血管疾患の治療または予防に用いるためのコレステリルエステル転送タンパク質（ｃｅｔｐ）阻害剤および当該阻害剤を含む医薬組成物
CA2958040C (en) * 2014-08-12 2022-09-13 Dezima Pharma B.V. Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
JP6956005B2 (ja) 2014-08-28 2021-10-27 デジマ・ファルマ・ベー・フェー コレステリルエステル転送タンパク質阻害剤及びＨＭＧ ＣｏＡ還元酵素阻害剤を含む医薬組成物及び治療併用剤
MX2017009534A (es) 2015-01-23 2018-04-10 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media.
WO2017023165A1 (en) 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
WO2017023166A1 (en) 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
WO2022177428A1 (en) * 2021-02-18 2022-08-25 Newamsterdam Pharma B.V. Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia
JP2024513155A (ja) * 2021-03-05 2024-03-22 ニューアムステルダム・ファルマ・ベー・フェー 認知症の治療のためのオビセトラピブ
CN113499860A (zh) * 2021-07-08 2021-10-15 江西新金叶实业有限公司 一种铜再生回收冶炼渣高效浮选方法
KR20240040767A (ko) 2021-07-26 2024-03-28 뉴암스테르담 파마 비.브이. His 저감반응자의 치료
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
WO2023129595A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
WO2024009144A1 (en) 2022-07-05 2024-01-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
WO2024042061A1 (en) 2022-08-22 2024-02-29 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2760237B1 (fr) * 1997-02-28 1999-04-16 Rhone Poulenc Rorer Sa Thiazolobenzoheterocycles, leur preparation et les medicaments les contenant
FR2763590B1 (fr) * 1997-05-22 2000-03-24 Synthelabo Derives d'acides[[[(arylmethyl)amino]carbonyl] alkyl]- aromatiques, leur preparation et leur application en therapeutique
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
JP2001348332A (ja) * 2000-04-07 2001-12-18 Takeda Chem Ind Ltd 可溶性ベータ・アミロイド前駆蛋白質分泌促進剤
JP2002053557A (ja) * 2000-08-14 2002-02-19 Japan Tobacco Inc アポリポ蛋白ａ−ｉ産生促進薬
NZ525614A (en) 2000-12-18 2005-03-24 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
SE0101161D0 (sv) * 2001-03-30 2001-03-30 Astrazeneca Ab New compounds
US20030216398A1 (en) 2001-04-05 2003-11-20 Mitsuru Kakihana Soluble beta amyloid precursor protein secretion promoters
IL162870A0 (en) 2002-02-01 2005-11-20 Pfizer Prod Inc Controlled release pharmaceutical dosage forms of a cholesteryl estertransfer protein inhibitor
WO2006012093A1 (en) 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
JP4531027B2 (ja) * 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物

Also Published As

Publication number Publication date
BRPI0509364B1 (pt) 2018-07-03
BRPI0509364B8 (pt) 2021-05-25
CA2560402C (en) 2011-09-13
KR100905684B1 (ko) 2009-07-03
ATE556077T1 (de) 2012-05-15
IL178195A (en) 2016-05-31
UA90269C2 (ru) 2010-04-26
BRPI0509364A (pt) 2007-09-04
EP1730152B1 (en) 2012-05-02
US20110039828A1 (en) 2011-02-17
ZA200608117B (en) 2007-12-27
US7872126B2 (en) 2011-01-18
PT1730152E (pt) 2012-05-21
US8158640B2 (en) 2012-04-17
EP1730152A2 (en) 2006-12-13
AR107377A2 (es) 2018-04-25
TWI338684B (en) 2011-03-11
ES2383900T3 (es) 2012-06-27
JP2007530443A (ja) 2007-11-01
MY158055A (en) 2016-08-30
AU2005228290B2 (en) 2008-07-17
US20070082896A1 (en) 2007-04-12
CN101381345A (zh) 2009-03-11
EA200601852A1 (ru) 2007-04-27
MXPA06011415A (es) 2006-12-20
WO2005095409A2 (en) 2005-10-13
CA2560402A1 (en) 2005-10-13
JP4565077B2 (ja) 2010-10-20
TW200536829A (en) 2005-11-16
EA011670B1 (ru) 2009-04-28
NZ550268A (en) 2009-08-28
ECSP066967A (es) 2007-01-26
DK1730152T3 (da) 2012-07-30
CN100528878C (zh) 2009-08-19
WO2005095409A3 (en) 2006-02-09
PL1730152T3 (pl) 2012-09-28
NO20065011L (no) 2006-12-29
AU2005228290A1 (en) 2005-10-13
KR20060135856A (ko) 2006-12-29
CN1938314A (zh) 2007-03-28
IL178195A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
AR048361A1 (es) Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos
AR048362A1 (es) Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos
AR059249A1 (es) Compuesto amina trisustituido
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
AR059248A1 (es) Heterociclos nitrogenados y sus usos como inhibidores de aterosclerosis. composiciones farmaceuticas
RU2348617C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
AR054214A1 (es) Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c.
ES2328820T3 (es) Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
AR025735A1 (es) Compuestos terapeuticos
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
AR057380A1 (es) Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
AR033306A1 (es) Compuestos
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
AR043038A1 (es) Compuestos de pirazolotriazina y usos de los mismos
AR046767A1 (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
EA201000101A1 (ru) Производные пиримидина 934
ES2531660T3 (es) Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
PE20040937A1 (es) Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4)
AR062360A1 (es) Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
AR054083A1 (es) Compuestos imidazol y su utilizacion paar preparar medicamentos
AR060623A1 (es) Compuestos derivados de 2-azetidinona y un metodo de preparacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FG Grant, registration